CHARLOTTESVILLE, VA –August 2, 2010 – Diffusion Pharmaceuticals LLC, a clinical-stage drug-development company, today announced that the U.S. Patent and Trademark Office (USPTO) has granted it patent no. 7,759,506 entitled “Bipolar Trans Carotenoid Salts and Their Uses.” This patent includes drug formulation and use claims relating to Diffusion’s entire family of first-in-class new chemical entities. [...]
CHARLOTTESVILLE, VA – Tuesday, April 8, 2008 – Diffusion Pharmaceuticals LLC, a clinical-stage drug-development company commercializing drugs utilizing a novel method of action that enhances oxygen diffusion, today announced that it has been granted U.S. patent no. 7,351,844 entitled “Bipolar Trans Carotenoid Salts and Their Uses.” This patent includes claims to a family of first-in-class [...]
CHARLOTTESVILLE, VA – December 21, 2007 – Diffusion Pharmaceuticals LLC, a clinical stage drug-development company commercializing first-in-class drugs utilizing a novel mechanism of action that enhances oxygen diffusion, today announced that one of its key advisors, Mr. Thomas Byrne, was recently recognized as a co-inventor of the underlying technology of Amgen’s blockbuster drug Aranesp® (darbepoietin [...]
CHARLOTTESVILLE, VA — Monday, February 9, 2004 — David G. Kalergis, JD/MBA, CEO of Diffusion Pharmaceuticals LLC, today announced that the company has received a $1.2 million grant (N00014-04-C-0146) from the Office of Naval Research (ONR) to support the transition of its novel small-molecule drug, trans sodium crocetinate (TSC), from animal to human testing. More [...]
